"*Stem Cell Biotech of the Year. This award goes to Advanced Cell Technology (ACT). ACT has had a relatively long, somewhat rollercoast-ish existence, but they really seem to have gotten their act together for the last several years. Their two clinical trials seem on track and they have an impressive scientific leadership.*"
Reading between the lines, I see:
1. They purposely mention scientific leadership, omitting the incredibly dismal management.
2. They use the words "clinical trials seem on track", meaning that they know nothing about behind closed doors, except, what we know,,,that the review board approved second cohort.
If they were honest, and perhaps disclosed their position in actc, they would acknowledge the many delays (Korea, Roslin, the next cohort, etc.), and mention the fact only one institution out of the 4 authorized is participating, and that, to date, the pps has declined dramatically on every positive news event during the entire year (2011).
I smell a pump. I'm not sure if these guys are able to own actc or not, but......